Follow us on Twitter
This page is updated frequently with new Arm-related patent applications. Subscribe to the Arm RSS feed to automatically get the update: related Arm RSS feeds. RSS updates for this page: Arm RSS
Mobile robot, positioning system of mobile robot, and positioning method of mobile robot
Pharmacy picking device comprising a universal supply- and- control module
|| List of recent Arm-related patents
|Controlled inventory refrigerated dispensing system|
A vending refrigerator for dispensing pharmaceutical products, such as vials, bottles, syringes, and the like, at a point of distribution, e.g., a doctor's office or pharmacy. The vending refrigerator comprises a first product dispenser for one type of packaging and a second product dispenser for a second type of packaging.
|Mobile robot, positioning system of mobile robot, and positioning method of mobile robot|
A mobile robot has a seating part, a moving apparatus to move the seating part, and a robot part with a base part to be attached to the seating part, a body capable of rotating around a vertical axis normal to an attaching surface which the seating part to be attached to the base part, and an arm connected to the body having a plurality of joints. The seating part has a first surface facing a work that is subject to the operation by the robot part and a second surface that is different from the first surface, and the arms are formed such that the positional relationship between the arms and the first surface is substantially identical to the positional relationship between the arms and the second surface according to the rotation of the body around the vertical axis..
|Pharmacy picking device comprising a universal supply- and- control module|
The invention relates to a pharmacy picking device (i) comprising a housing (i 0) with a plurality of shelf bases (ii) disposed one above the other, at least one operating device (12) a conveyor device (14), a housing-coupling interface (15), and a universal supply-and-control module (20). This universal supply-and-control module (20) comprises a feed device (21), an identification end measurement device (22), operator input/output devices (23), an electronic controller (24) and a voltage supply assembly (25), as well as a housing-coupling interface and en electrical interface (27), said supply-and-control module (20) being arranged adjacent to the housing (10) such that a mechanical coupling is produced by said housing-coupling interface (15) and module-coupling interface (26), in such a manner that drug packages in or on the supply-and-control module (20), which are to be deposited, are delivered to a position on the conveyor device (14) which is known to the electronic controller..
Endosseous implant to be applied to a human or animal bone, wherein the surface of the implant is made from titanium or a titanium alloy, said implant having a smooth or rough surface texture, which is characterized in that said surface has been treated with at least one selected organic phosphonate compound or a pharmaceutically acceptable salt or ester or an amide thereof; process for producing said implants.. .
|Insertion instrument for intervertebral implants|
An insertion tool for positioning intervertebral spacers into disc spaces. The insertion tool has a proximal end and a distal end, a t-handle secured to the proximal end and a pair of alignment rails extending to the distal end.
|Cross connector system|
The present teachings provide one or more surgical implements for repairing damaged tissue, such as in the case of a spinal fixation procedure. A cross connector system for use during a spinal fixation procedure is provided.
|Body conforming disposable absorbent article having leg wraps and internal topsheet and method of making same|
A secondary internal topsheet and leg wrap structure is provided in a disposable absorbent garment such as a diaper or training pants. The leg wrap structure has a base layer, a top layer, and an elastic construction disposed inbetween.
|Method and system for monitoring oxygenation levels of compartments and tissue|
A method and system for continually monitoring oxygenation levels in real-time in compartments of an animal limb, such as in a human leg or a human thigh or a forearm, can be used to assist in the diagnosis of a compartment syndrome. The method and system can include one or more near infrared compartment sensors in which each sensor can be provided with a compartment alignment mechanism and a central scan depth marker so that each sensor may be precisely positioned over a compartment of a living organism.
|Process for preparing new tiotropium salts, new tiotropium salts as such and pharmaceutical compositions thereof|
The invention relates to a process for preparing new tiotropium salts, these new tiotropium salts as such, pharmaceutical formulations containing them and their use for preparing a medicament.. .
|Modulators of toll-like receptors|
Pharmaceutically acceptable salts thereof, compositions containing such compounds, and therapeutic methods that include the administration of such compounds.. .
|Processing aids for use in manufacturing extruded polystyrene foams using low global warming potential blowing agents|
A foamable polymeric mixture is provided that includes a polymer composition and at least one blowing agent. The blowing agent may comprise any blowing agents known not to deplete the ozone or increase the prevalence of global warming, such as co2, hfo, hfc and mixtures thereof.
|Novel sulphur containing lipids for use as food supplement or as medicament|
The present disclosure relates to lipid compounds of general formula (i) wherein r1 is chosen from a c10-c22 alkyl group, a c10-c22 alkenyl group having 1-6 double bonds, and a c10-c22 alkynyl group having 1-6 triple bonds; r2 and r3 are the same or different and may be selected from different substituents; y is chosen from sulphur, sulfoxide, and sulfone; and x is a carboxylic acid or a derivative thereof, a carboxylic ester, a carboxylic anhydride, or a carboxamide; or a pharmaceutically acceptable salt, complex, or solvate thereof. The present disclosure also relates to pharmaceutical compositions and lipid compositions comprising such compounds, and methods of using such compounds such as for treating diseases related to cardiovascular, metabolic, and/or inflammatory diseases..
|Arginine methyltransferase inhibitors and uses thereof|
Described herein are compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds of the present invention are useful for inhibiting arginine methyltransferase activity.
|Cytotoxic and anti-mitotic compounds, and methods of using the same|
Including stereoisomers, pharmaceutically acceptable salts and prodrugs thereof, wherein r1, r2, r3, r4 and r5 are as defined herein. Methods associated with preparation and use of such compounds, as well as pharmaceutical compositions comprising such compounds, are also disclosed.
|Combination therapy of hsp90 inhibitory compounds with mtor/p13k inhibitors|
A pharmaceutical composition comprising an mtor/pi3k inhibitor, and an hsp90 inhibitor according to the following formulae (i) and (ia) or tautomers, or pharmaceutically acceptable salts thereof, wherein the variables in the structural formulae are defined herein. Also provided are methods for treating a proliferative disorder in a subject in need thereof, using pharmaceutical compositions described herein..
This invention relates to novel morphinan compounds and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering a σ1 receptor agonist that also has nmda antagonist activity..
|Sustained release formulation of nalbuphine|
Sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; methods for making the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof; and methods for using the sustained release formulations of nalbuphine or pharmaceutically acceptable salts thereof to treat patients suffering from pain are provided.. .
|Fast release solid oral compositions of entecavir|
The present invention is directed to fast release pharmaceutical compositions comprising entecavir or its pharmaceutically acceptable salts, process for preparing the same and use of such compositions for the treatment of hepatitis b virus infection.. .
|Inhibitors of hiv replication|
The present invention relates to novel 2,3,4-substituted 5,6,7,8-tetrahydrobenzothieno[2,3-b]pyridine compounds and pharmaceutically acceptable salts thereof, to compositions containing such compounds and to the use of such compounds as inhibitors of hiv replication.. .
|1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine as a compound with combined serotonin reuptake, 5-ht3 and 5-ht1a activity for the treatment of cognitive impairment|
This disclosure relates to 1-[2-(2,4-dimethylphenylsulfanyl)-phenyl]piperazine or a pharmaceutically acceptable salt thereof in a crystalline form.. .
|Highly selective sigma receptor ligands|
In which r1 can be a radical of an optionally substituted c-4 to c-7 n-containing heterocycle such as, for example, radicals of optionally substituted piperidines, optionally substituted piperazines, optionally substituted tetrahydropyridines, optionally substituted azepanes, tertiary amines (cyclic or acyclic), isoindoline-1,3-dione, or optionally substituted tetrahydroisoquinolones (aromatically substituted): r2,3,4,5,6 can each independently be any one or combinations of the following moieties, cyano, nitro, acyl, alkyl, amido, azido, isothiocyanate, isocyanate optionally substituted anilino, halogens, ethers, sulfonamides, thioacyl, nitro, aromatic, heterocyclic, olefinic, acetylene, deuterium, or tritium; y can be either ch, ch2, o, s, och2, n—r, n—ar, c—r, c—ar; z can be either h, o, s, s—r or nr. R groups can be either h, aryls, alkyls, or cycloalkyls; “n” can be 1 to 5 carbons in length and stereoisomers, functional analogs, and pharmaceutically acceptable salts thereof and wherein the moiety bridging r1 and n can be optionally substituted alkylene, optionally substituted alkenylene or optionally substituted alkynylene and where the alkylene group can include an inserted c3-c5 cycloalkyl group, aromatic and heterocyclic group..
|Macrocycles that increase p53 activity and the uses thereof|
The present invention provides a compound of formula (1): as described herein or a pharmaceutically acceptable salt or solvate thereof. The compounds are useful as inhibitors of the hdm2 protein.
Compounds of formula i, as shown below and defined herein: pharmaceutically acceptable salts thereof, synthesis, intermediates, formulations, and methods of disease treatment therewith, including treatment of cancers, such as tumors driven or mediated at least in part by rsk. This abstract is not limiting of the invention..
|Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one|
Provided herein are formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one.. .
|Arginine methyltransferase inhibitors and uses thereof|
Described herein are compounds of formula (i), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity.
|1,4- dihydropyridine derivatives with hsp modulating activity|
The invention provides 1,4-dihydropyridine derivatives of formula (i) wherein r1 is optionally substituted c6-24aryl group or 5 to 6 membered heteroaryl group comprising 1 to 3 nitrogen atoms or other heteroatoms like oxygen and sulphur, and combinations thereof; r2 and r3 are independently hydrogen or c1-6alkyl group; r4 and r5 are independently hydrogen, c1-6alkyl group optionally substituted with amino, mono- or di(c1-6alkyl)amino, or with 5 to 24 membered optionally fused heterocyclic ring attached by nitrogen and optionally comprising additional 1 to 3 n, o, s heteroatoms and optionally substituted with c1-6alkyl group or c1-6 alkoxy group; r6 is c1-6alkyl, c3-7cycloalkyl, c3-7cycloalkylc1-6alkyl or arylc1-6alkyl group; and stereoisomers including enantiomers, diastereomers, racemic mixtures, mixture of enantiomers and combination thereof, as well as polymorphs, pharmaceutically acceptable salts, solvates, esters and prodrugs thereof for use in the therapeutic or prophylactic treatment of a disorder mediated by heat shock proteins.. .
|Use of (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane to treat addictive and alcohol-related disorders|
The present invention relates to (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane and pharmaceutically acceptable salts thereof, compositions comprising (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or a pharmaceutically acceptable salt thereof, and methods for treating or preventing an alcohol-related or addictive disorder. The (+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane or pharmaceutically acceptable salt thereof is preferably substantially free of its corresponding (+)-enantiomer.
|Hydroxamate derivatives for hdac inhibitor, and the pharmaceutical composition comprising thereof|
The present invention relates to a novel hydroxamate derivatives, more specifically, to novel hydroxamate derivatives having inhibitory activity against histone deacetylase (hdac), isomers thereof, pharmaceutically acceptable salts thereof, hydrates or solvates thereof, use for preparing pharmaceutical compositions, pharmaceutical compositions comprising the same, treatment method using said composition, and a preparing method of novel hydroxamate derivatives. The novel selective hydroxamate derivatives having inhibitory activity against histone deacetylase (hdac) compositions can be used for treatment of inflammatory disease, rheumatoid arthritis, or degenerative disease..
|Therapeutically active thiazolo-pyrimidine derivatives|
A series of thiazolo[5,4-d]pyrimidine derivatives of formula (i) or an n-oxide thereof, or a pharmaceutically acceptable salt or solvate thereof: (i) q represents a group of formula (qa), (qb), (qc), (qd) or (qe) are beneficial in the treatment and/or prevention of various human ailments, including inflammatory, autoimmune and oncological disorders; viral diseases; and organ and cell transplant rejection.. .
The invention provides a compound of formula (i as defined herein, pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variables are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions..
Or a pharmaceutically acceptable salts thereof, wherein x, z, r1a, r1b, r2, r3, r4 and r5 are as defined in the description, and to their use in medicine, to compositions containing them, to processes for their preparation and to intermediates used in such processes. The compounds of formula (i) are nav1.7 inhibitors useful in the treatment of a wide range of disorders, particularly pain..
|Hybrid diazeniumdiolated compounds, pharmaceutical compositions, and method of treating cancer|
Disclosed are hybrid compounds that release both nitric oxide and a moiety that inhibits poly (adp-ribose) polymerase (parp), e.g., a compound or a pharmaceutically acceptable salt thereof of formula (i), wherein r1-4 and m-p are as described herein. Also disclosed are pharmaceutical compositions and methods of use including treating cancer and enhancing the chemotherapeutic treatment of chemotherapeutic agents and high energy radiation..
|Hsp90 inhibitors with modified toxicity|
The invention provides 19-substituted geldanamycin derivatives, and pharmaceutically acceptable salts thereof that are potent hsp90 binding agents useful for the treatment of, and/or the amelioration of symptoms of, cancer or neurodegenerative disorders.. .
|Peptide compounds for suppressing inflammation|
Provided herein are peptides that exhibit apoe biological activity, as well as compositions and pharmaceutical formulations that include the peptides. The peptides, compositions, and methods disclosed herein have broad applications as they can be used to treat a broad spectrum of injury, diseases, disorders, and clinical indications..
|Amorphous ezatiostat ansolvate|
Provided herein is an amorphous form of a pharmaceutically acceptable salt of ezatiostat, for example, ezatiostat hydrochloride, compositions, uses and methods of preparation thereof.. .
|Air duct sealing system for obstructing or directing airflow through portions of an air duct system|
The present invention discloses adjustable air duct sealing systems for obstructing airflow through portions of an air duct system. Such systems may include an adjustable frame assembly configured to allow changes to a perimeter of the adjustable frame assembly.
|Fixation releasing device|
A fixation releasing device by which a buoyant body and a weight may be securely fixed and the fixed state between the buoyant body and the weight may be readily released, using a simple structure. The fixation releasing device is made from a buoyant body, a weight, and a connection designed to connect the buoyant body and weight.
An electrical connector includes an insulating body, a plurality of terminals integrated in the insulating body, a strengthening structure and a shell mounted around the insulating body. The insulating body has a base portion and a tongue portion extending forward from a front face of the base portion.
|Electrical connector with high reliability|
An electrical connector (100) includes an insulative housing (2), a number of contacts (3) retained in the insulative housing, a metal shield (4) covering the insulative housing for defining a receiving space, an insulative cover (5) insert-molded outside of the metal shield, and a metal frame (6) retained in the insulative cover. The metal frame includes a transverse arm (61) and a pair of vertical arms (62) extending downwardly from two distal ends of the transverse arm for reinforcing the metal shield from three sides of the metal shield..
|Assembly comprising an adapter and a smart card|
In an assembly including an adapter and a smart card, the outer dimensions of the adapter are compliant with the 3ff microcircuit card format, the format further defining the positioning and minimum dimensions of contact areas; the smart card includes a plurality of contact surfaces, the dimensions of which are greater than those defined by the 3ff format for the contact areas, the outer dimensions of the card being smaller than those of the 3ff format; and the adapter includes a recess, the outline of which is defined by a plurality of arms that surround the recess, the recess being shaped so as to receive the smart card so the contact areas of the adapter fit inside the contact surfaces of the smart card, each of the contact areas being off-center relative to each of the contact surfaces, so each arm has a width of 700 micrometers, ensuring mechanical stability.. .
|Swim simulator with breathing practice function|
The invention is related to a swimming teaching apparatus which provides user to make a complete swimming like action on land. The special technical features are a body rotation mechanism, arms guide, a breathing sink and a kick pad for legs, all together to perform on land swimming exercise.
A dental articulator is provided in which at least one of the two arms thereof has a base member that is articulated with respect to a bracket element onto which a dental model may be mounted, allowing independent movement of the dental model with respect to the pivot axis hingedly linking the arms.. .
|Health supplement using guarana extract|
The current invention is a supplement made from a combination of herbs, vitamins, amino acids which in the preferred embodiment is a 100% vegetarian liquid capsules that are ingested allow for rapid absorption. The components of the supplement can be mint or menthol such as peppermint or spearmint, methyl b12 or b12, niacin, guarana, dimethylaminoethanol, acetyl-l-carnitine or alcar, ocimum tenuiflorum, one or more teas such as green tea, white tea or black tea, ginkgo, rhodiola rosea, phosphatidylserine, tyrosine, l-alpha glycerylphosphorylcholine, citicoline (inn), huperzine a, and vinpocetine..
|Method for purifying bee venom on mass scale|
Disclosed is a method for the purification of bee venom on a mass scale. It comprises dissolving crude bee venom in a solvent to form a bee venom solution; applying an adsorbent to the bee venom solution to form a mixture; and removing the adsorbent through filtration to afford a pure bee venom solution.
|Pharmaceutical compositions of antihypertensives|
The present invention describes antihypertensive pharmaceutical formulations particularly formulations of losartan and indapamide.. .
|Multiple unit pharmaceutical formulation|
An orally disintegratable benzimidazole formulation, featuring a plurality of compressed pellets in a mups tablet. The individual units feature a substrate with the active ingredient and an enteric coating, optionally with a subcoating between the substrate and the enteric coating.
|Method and compositions for cellular immunotherapy|
The present invention provides methods and compositions to confer and/or augment immune responses mediated by cellular immunotherapy, such as by adoptively transferring genetically modified tumor specific cd8+ t cells in the presence of tumor-specific, subset specific genetically modified cd4+ t cells, wherein the cd4+ t cells confer and/or augment a cd8+ t cells ability to sustain anti-tumor reactivity and increase and/or maximize tumor-specific proliferation of the tumor-specific cd8+ t cells of interest. Pharmaceutical formulations produced by the method, and methods of using the same, are also described..
|Formulation of human antibodies for treating tnf-alpha associated disorders|
A liquid aqueous pharmaceutical formulation is described which has a high protein concentration, a ph of between about 4 and about 8, and enhanced stability.. .
The invention provides stable aqueous pharmaceutical formulations comprising a therapeutic antibody, trehalose, a buffer, and optional surfactant, and having a ph in the range of about 5.5 to about 7.0. The invention also provides methods for making such formulations and methods of using such formulations..
|Methods of treatment with deferiprone|
The current application is directed to methods of treating or ameliorating myocardial ischemia, an acute coronary event, and a myocardial reperfusion injury comprising administering a therapeutically effective amount of deferiprone or a pharmaceutically acceptable salt thereof to a patient in need thereof. The application is also directed to reducing the risk for myocardial reperfusion injury as well as promoting the beneficial remodeling of cardiac tissue in a patient, comprising administering a therapeutically effective amount of deferiprone or a pharmaceutically acceptable salt thereof to a patient before, during or after reperfusion therapy.
|Handling device and methods|
An article handling apparatus including a frame adapted to receive the article on a support means; a plurality of wheels attached to said frame for movement of said frame over a substrate surface; and retaining arms operatively coupled to the frame and adapted to releasably secure the article to the frame. The secured article is movable in a controlled manner with respect to the frame by movement of the support means and the retaining arms..
|Watercraft locking assembly|
A detachable fin is secured to a socket imbedded into the bottom layer of a watercraft such as a surfboard, wind surf board, standup paddle board, or kayak for example, by a mechanism including a screw whose head which is captured into a slot in the socket, and which passes through a hole in a spur projecting from the portion of the fin inserted into the slot. Two pivotally joined arms engaged over the screw astride a nut and forming a surrounding sleeve.
Popular terms: [SEARCH]
Follow us on Twitter
This listing is a sample listing of patent applications related to Arm for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Arm with additional patents listed. Browse our RSS directory or Search for other possible listings.